Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 6/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 3/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7324420 | 0.81 | CEL (0.43) | SLC6A2SLC6A3SLC6A4CYP2D6KCNH2 | |
| SCHEMBL7261225 | 0.80 | SLC6A2 (0.42) | SLC6A2SLC6A3NPSR1SMN1; SMN2SLC6A4 | |
| SCHEMBL28730824 | 0.80 | SLC6A2 (0.42) | SLC6A2SLC6A3NPSR1SMN1; SMN2SLC6A4 | |
| SCHEMBL13915011 | 0.80 | SLC6A2 (0.39) | SLC6A2SLC6A3NPSR1CYP3A4SMN1; SMN2 | |
| SCHEMBL28730826 | 0.78 | MDM2 (0.43) | SLC6A2SLC6A3TAAR1FFAR1 | |
| SCHEMBL28730828 | 0.78 | MDM2 (0.43) | SLC6A2SLC6A3TAAR1FFAR1 | |
| SCHEMBL29576656 | 0.78 | MDM2 (0.43) | SLC6A2SLC6A3TAAR1FFAR1 | |
| SCHEMBL28730844 | 0.76 | CA1 (0.38) | MAOBESR1ESR2 | |
| SCHEMBL28730840 | 0.76 | CA1 (0.38) | MAOBESR1ESR2 | |
| SCHEMBL29576393 | 0.76 | CA1 (0.38) | MAOBESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0295050-B1 | PROCESS FOR PREPARING A 4,4-DIPHENYLBUTANOIC ACID DERIVATIVE | PFIZER INC. (US) | 1991-04-17 | — | — | EP | claimed |
| US-4839104-A | Process for preparing sertraline intermediates | PFIZER, INC. (US) | 1989-06-13 | — | — | US | claimed |
| EP-0295050-A1 | Process for preparing a 4,4-diphenylbutanoic acid derivative | PFIZER INC. (US) | 1988-12-14 | — | — | EP | claimed |
| US-4777288-A | Process for preparing a 4,4-diphenylbutanoic acid derivative | PFIZER INC. (US) | 1988-10-11 | — | — | US | claimed |
| JP-1009953-A | — | — | None | — | — | JP | disclosed |
| US-9751877-B2 | Substituted pyrido[1,2-a]pyrazines for the treatment of neurodegenerative and neurological disorders | PFIZER INC. (US) | 2017-09-05 | — | — | US | disclosed |
| EP-2897956-B1 | NOVEL BICYCLIC PYRIDINONES | PFIZER (US) | 2016-11-09 | — | — | EP | disclosed |
| US-20160024088-A1 | Novel Pyrido[1,2-a]Pryazines And Their Use in the Treatment of Neurodegenerative and Neurological Disorders | PFIZER INC. | 2016-01-28 | — | — | US | disclosed |
| US-9193726-B2 | Substituted pyrido[1,2-a]pyrazines for the treatment of neurodegenerative and neurological disorders | PFIZER INC. (US) | 2015-11-24 | — | — | US | disclosed |
| EP-2897956-A1 | NOVEL BICYCLIC PYRIDINONES | Pfizer Inc. (US) | 2015-07-29 | — | — | EP | disclosed |
| US-20150072990-A1 | Novel Pyrido[1,2-a]Pryazines And Their Use In The Treatment of Neurodegenerative and Neurological Disorders | PFIZER INC. | 2015-03-12 | — | — | US | disclosed |
| US-8916564-B2 | Substituted pyrido[1,2-a]pyrazines for the treatment of neurodegenerative and neurological disorders | PFIZER INC. (US) | 2014-12-23 | — | — | US | disclosed |
| WO-1993012062-A1 | PROCESS FOR PREPARING KETONE ENANTIOMER | PFIZER INC. (US) | 1993-06-24 | — | — | WO | disclosed |
| EP-0295050-B1 | PROCESS FOR PREPARING A 4,4-DIPHENYLBUTANOIC ACID DERIVATIVE | PFIZER INC. (US) | 1991-04-17 | — | — | EP | disclosed |
| US-4839104-A | Process for preparing sertraline intermediates | PFIZER, INC. (US) | 1989-06-13 | — | — | US | disclosed |
| US-4839104-A | Process for preparing sertraline intermediates | PFIZER, INC. (US) | 1989-06-13 | — | — | US | disclosed |
| EP-0295050-A1 | Process for preparing a 4,4-diphenylbutanoic acid derivative | PFIZER INC. (US) | 1988-12-14 | — | — | EP | disclosed |
| EP-0295050-A1 | Process for preparing a 4,4-diphenylbutanoic acid derivative | PFIZER INC. (US) | 1988-12-14 | — | — | EP | disclosed |
| US-4777288-A | Process for preparing a 4,4-diphenylbutanoic acid derivative | PFIZER INC. (US) | 1988-10-11 | — | — | US | disclosed |
| US-4777288-A | Process for preparing a 4,4-diphenylbutanoic acid derivative | PFIZER INC. (US) | 1988-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150072990-A1 | Novel Pyrido[1,2-a]Pryazines And Their Use In The Treatment of Neurodegenerative and Neurological Disorders | PRNP, SNCA, PSEN1 | SLC6A2 332/4885SLC6A3 379/4885NPSR1 975/4885 |
| US-20160024088-A1 | Novel Pyrido[1,2-a]Pryazines And Their Use in the Treatment of Neurodegenerative and Neurological Disorders | PRNP, SNCA, PSEN1 | SLC6A2 332/4885SLC6A3 379/4885NPSR1 975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.